Qlucore AB (publ) have passed the evaluation phase for a prestigious grant of SEK 27 million to accelerate the clinical cancer diagnostics solutions for acute myeloid leukemia (AML) as well as bladder cancer. The targeted cancer disease areas are important because both cancer types have multiple changes on the RNA level that can be utilized to improve diagnosis and treatment. However this information is not fully used to provide the right therapy for the right patient.

The project aims to change this. The recognition from the expert review panels of the solutions and the addressed clinical need further strengthens the belief in the strategic direction and the focus on solutions based on RNA. RNA-based solutions are gaining momentum, allowing for cancer classification using gene fusions and gene expression signatures.

RNA-seq can reliably detect gene fusions and measure gene expression levels, thereby providing more insights into cancer biology. The grant will strengthen the financial position of Qlucore. A formal grant agreement phase will now take place and from earlier calls company estimate that it will be concluded before the summer of 2024.

The EIC Accelerator grant is awarded in tough competition.